Biopharmaceutical Company

A clinical-stage biopharmaceutical company developing easy-to-administer oral medications for indications that affect large under-served patient populations.

Challenge

In 2022, the company had contacted RBW Strategy as they received several federal awards and would benefit from institutional background in managing and maintaining compliance. In partnership with one of our consulting partners, MJ White Consulting, RBW Strategy began to assist the company with the increased compliance and grants management burdens tied to the administration of federal research grant awards.

Outcome

RBW Strategy worked with the company to navigate the administrative challenges and maintain grant compliance after the company’s IPO. In addition to developing and submitting a Negotiated Indirect Cost Rate Agreement, our team developed policies and procedures that are compliant with federal policy requirements.

Services provided

Since the beginning of our work together, our team has provided the day-to-day grants management of millions of dollars in research funding, including technical assistance, report development, internal grant policy updates, financial and programmatic guidance related to grant management, and other as-needed support related to the administration of federal-funded awards.

Let’s work together

Create a more sustainable future.